Funded Biotechnology Startups in Woburn
Disclosed round sizes in this Woburn biotechnology set cluster tightly below the top line: Sanegene Bio’s $110M Series B (2025-12-08) is the largest disclo…
Disclosed round sizes in this Woburn biotechnology set cluster tightly below the top line: Sanegene Bio’s $110M Series B (2025-12-08) is the largest disclosed amount, with the next-largest disclosed rounds at $140M (Replimune Group, 2024-11-25) and $60M (Neurogastrx, 2021-08-26), leaving most other disclosed entries in single-digit millions ($1M to $40M) such as Purinomia Biotech’s $1M (2024-06-07) and Fieldstone Bio’s $5M (2025-05-15).
The geography is consistent across all 14 rows, with every company listed in Woburn, Massachusetts, and the timeline spans 2021-08-26 (Neurogastrx, $60M) through 2026-06-13 (Zumutor Biologics, $7M). Stage/structure is mixed but opaque: “Series Unknown” appears in 7 of the 14 rows (e.g., MarvelBiome $40M on 2025-10-22; Hopewell Therapeutics $3M on 2025-09-21), and “undisclosed” amounts appear in 2 rows (100XBIO on 2025-12-27; Leveragen on 2025-07-25).
Most recent rounds
14 shownRelated listings
Frequently asked
What are the size outliers among the disclosed rounds, and how far above the bulk do they sit?
Replimune Group’s $140M (2024-11-25) is the highest disclosed amount, while Sanegene Bio’s $110M (2025-12-08) is the next-highest disclosed. By contrast, several disclosed rounds are in the lower single digits or teens, including Purinomia Biotech’s $1M (2024-06-07) and Fieldstone Bio’s $5M (2025-05-15).
Does the list cluster in time, or is funding spread evenly across the displayed window?
Most of the most recent activity is concentrated in 2024–2026: multiple disclosed rounds appear between 2025-05-15 (Fieldstone Bio, $5M) and 2025-12-08 (Sanegene Bio, $110M). The oldest disclosed entry shown is Neurogastrx at $60M on 2021-08-26, with no disclosed rounds in the intervening years besides 2022-08-15 (Frequency Therapeutics, amount undisclosed).
Which entries closed in the most recent 90 days of the shown dataset, and do any amounts stand out?
Within the latest window anchored by 2026-06-13 (Zumutor Biologics, $7M), the 90-day span includes Zumutor Biologics (2026-06-13, $7M) and the preceding three dated rows in late 2025 (100XBIO on 2025-12-27, amount undisclosed; Sanegene Bio on 2025-12-08, $110M; MarvelBiome on 2025-10-22, $40M). The standout within this slice is Sanegene Bio at $110M.
How dominant is “Series Unknown,” and what does that imply for stage comparisons?
“Series Unknown” accounts for 7 of the 14 rows, including MarvelBiome ($40M on 2025-10-22) and Replimune Group ($140M on 2024-11-25). Because 5 additional rows are explicitly labeled (e.g., Series B: Zumutor Biologics $7M on 2026-06-13; Neurogastrx $60M on 2021-08-26; Seed: Fieldstone Bio $5M on 2025-05-15; Pre-Seed and Series A), stage-based ranking using disclosed amounts will be distorted by missing stage labels.
Are there geographic concentrations or repeated locality patterns, or is location uniform?
Location is uniform across the 14 rows: every company is listed in Woburn, Massachusetts, United States. There are no alternate city entries (e.g., other Massachusetts towns) within this subset, so geographic variation does not drive differentiation here.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.